Martin Pharmaceuticals Secures Exclusive Rights From Mitsubishi Tanabe Pharma for Docarpamine to Treat Decompensated Chronic Liver Disease Including Ascites [Yahoo! Finance]
MITSUBISHI CH GRP U/ADR (MTLHY)
NASDAQ:AMEX Investor Relations:
mitsubishichem-hd.co.jp/english/ir
Company Research
Source: Yahoo! Finance
treatment of complications arising from advanced liver disease, today announced that it has entered into a license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for exclusive access to docarpamine-related toxicology, preclinical, clinical safety, and pharmacokinetics data in the field of gastrointestinal conditions, including ascites, for use outside of Japan and China . Under the terms of the agreement, MTPC will receive an undisclosed upfront payment and additional milestones and royalties. "This license agreement with MTPC, a global leader in the pharmaceutical industry, will help us rapidly advance the development of CIQUAAX," said Sven Jacobson , Chief Executive Officer of Martin Pharmaceuticals. "We are grateful to be able to access MTPC's years of experience with docarpamine and are excited by the potential of CIQUAAX given the significant unmet need for a safe and effective therapy for patients with decompensated chronic liver disease." This announcement follo
Show less
Read more
Impact Snapshot
Event Time:
MTLHY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MTLHY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MTLHY alerts
High impacting MITSUBISHI CH GRP U/ADR news events
Weekly update
A roundup of the hottest topics
MTLHY
News
- Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items [Yahoo! Finance]Yahoo! Finance
- Mitsubishi Tanabe Pharma America Announces Research Collaboration Between Mitsubishi Tanabe Pharma Corporation and Dewpoint Therapeutics to Advance Small Molecule Condensate Modulator for ALS [Yahoo! Finance]Yahoo! Finance
- Classiq, Deloitte Tohmatsu, and Mitsubishi Chemical Compress Quantum Circuits by Up to 97% [Yahoo! Finance]Yahoo! Finance
- Government of Canada announces investment in Québec-based Aramis Biotechnologies [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Mitsubishi Tanabe Pharma America to Present Data on Investigational ND0612 at the 2024 Annual Meeting of the Parkinson Study Group [Yahoo! Finance]Yahoo! Finance